Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Cti Biopharm Corp (NASDAQ: CTIC)

$3.91 USD -$0.04 (-1.01%)
Last Price $3.91
Net Change $-0.04 (-1.01%)
Bid $0
Ask Price $0
Open Price $3.95
Previous Close Price $3.95
High Price $4.05
Low Price $3.9
Number of Trades 223
Volume 56,800
Fifty Two Week High $6.48 (2017-01-09)
Fifty Two Week Low $3.1 (2016-06-27)
Average Daily Volume 216,974
Share Outstanding 28,230 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $-61.29
Recent Earnings $
Annual EPS $-1.83
Last Quarter EPS $
Market Capitalization $0.11B
Insider Shareholders % 0.0808%
Annual Revenue $0B
No. Shares Outstanding 28,230
Inst. Shareholder % 0%
Annual Net Income $0B
TTM Net Profit Margin $100.76
1-Year Return -30.18%
3-Year Return -87.7%
5-Year Return -93.08%
5-Year Revenue Growth 0%
5-Year Earnings Growth -95.17%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -61.290001%
Dividends per Share $
Stock Split Ratio 1-10
Beta 0.78
CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington.

CTIC News & Stock Updates